Reactome | PDGFRs bind type II TKI

authored

[InstanceEdit:9677035] Rothfels, Karen, 2020年02月25日

category binding

compartment

created [InstanceEdit:9674096] Rothfels, Karen, 2020年01月10日

dbId 9674095

displayName PDGFRs bind type II TKI

edited

[InstanceEdit:9677035] Rothfels, Karen, 2020年02月25日

eventOf

[Pathway:R-HSA-186797] Signaling by PDGF - Homo sapiens

input

isChimeric false

isInDisease false

isInferred false

literatureReference

[LiteratureReference:9674200] Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
[LiteratureReference:9674255] Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib)
[LiteratureReference:2077545] E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
[LiteratureReference:9674254] Inhibition of PDGF, TGF-?, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib
[LiteratureReference:9674181] BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
[LiteratureReference:9674295] Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases
[LiteratureReference:9674174] BAY 43-9006: preclinical data
[LiteratureReference:9674258] Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment
[LiteratureReference:9674233] In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
[LiteratureReference:9674288] Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
[LiteratureReference:9673583] The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders
[LiteratureReference:9674290] The PDGF/PDGFR pathway as a drug target
[LiteratureReference:9674274] Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

maxDepth 1

modified [InstanceEdit:10867632] Weiser, Joel, 2025年08月27日

name

PDGFRs bind type II TKI

orthologousEvent

output

[Complex:R-HSA-9674086] PDGFR:type II PDGFR-binding TKIs [plasma membrane]

releaseDate 2020年03月17日

reviewStatus [ReviewStatus:9821382] five stars

reviewed

[InstanceEdit:9676030] Ip, Carman K M, 2020年02月06日

schemaClass Reaction

species

[Species:48887] Homo sapiens

stId R-HSA-9674095

summation

[Summation:9674091] Wild-type PDGFRA and PDGFRB can be bound and inhibited by cl...

Reactome Pathway Database

Reactome Pathway Database

PDGFRs bind type II TKI Show undefined attributes

Referrals

Cite Us!

Download As: